Pyxis Oncology completes MICVO enrollment and appoints new interim leadership
Pyxis Oncology (NASDAQ:PYXS), a clinical-stage biopharmaceutical company focused on next-generation therapeutics for difficult-to-treat cancers, announced it has completed target enrollment of approximately 40 patients in the Phase 1 monotherapy dose-expansion cohort of micvotabart pelidotin (MICVO) in patients with second-line or later recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).





-640x360.jpg&w=1200&q=75)
-640x360.jpg&w=1200&q=75)











-640x360.webp&w=1200&q=75)

